2 diabetes drugs up for FDA safety review in April

03/9/2009 | CNNMoney

An FDA advisory committee is scheduled next month to examine whether Bristol-Myers Squibb's saxagliptin and Novo Nordisk's liraglutide increase the risks of heart attack and stroke in patients with Type 2 diabetes. The move is in line with the agency's guidance issued in December.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice President - Government Products
Health Alliance Plan
Detroit, MI
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Meridian Health Plan
Detroit, MI
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
President/Chief Executive Officer
Winston-Salem, NC